Trade Fulgent Genetics, Inc. - FLGT CFD

Add to favourite

20.05

0.1%

0.14

Low: 19.89

High: 20.36

Market Trading Hours* (UTC) Opens on Friday at 13:30

Mon - Fri: 13:30 - 20:00

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.14

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Fulgent Genetics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	20.03
Open*	19.89
1-Year Change*	-35.51%
Day's Range*	19.89 - 20.36
52 wk Range	23.09-44.09
Average Volume (10 days)	146.01K
Average Volume (3 months)	4.32M
Market Cap	774.02M
P/E Ratio	-100.00K
Shares Outstanding	29.63M
Revenue	286.41M
EPS	-2.14
Dividend (Yield %)	N/A
Beta	1.51
Next Earnings Date	Feb 26, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	20.05	0.10	0.50%	19.95	20.38	19.75
Apr 17, 2024	20.03	-0.66	-3.19%	20.69	20.80	20.01
Apr 16, 2024	20.67	0.22	1.08%	20.45	20.86	20.26
Apr 15, 2024	20.68	0.13	0.63%	20.55	20.75	20.45
Apr 12, 2024	20.73	-0.12	-0.58%	20.85	20.94	20.55
Apr 11, 2024	20.98	0.07	0.33%	20.91	21.10	20.56
Apr 10, 2024	21.09	-0.07	-0.33%	21.16	21.28	20.90
Apr 9, 2024	21.82	0.67	3.17%	21.15	21.82	21.15
Apr 8, 2024	21.20	0.09	0.43%	21.11	21.32	20.93
Apr 5, 2024	21.22	0.37	1.77%	20.85	21.38	20.80
Apr 4, 2024	21.14	0.18	0.86%	20.96	21.69	20.95
Apr 3, 2024	21.07	0.17	0.81%	20.90	21.15	20.60
Apr 2, 2024	21.19	-0.14	-0.66%	21.33	21.33	21.07
Apr 1, 2024	21.76	0.16	0.74%	21.60	21.82	21.11
Mar 28, 2024	21.63	0.01	0.05%	21.62	22.09	21.62
Mar 27, 2024	21.63	0.06	0.28%	21.57	21.89	21.57
Mar 26, 2024	21.58	-0.26	-1.19%	21.84	22.17	21.53
Mar 25, 2024	22.06	0.41	1.89%	21.65	22.06	21.65
Mar 22, 2024	21.76	0.35	1.63%	21.41	21.81	21.16
Mar 21, 2024	21.50	-0.40	-1.83%	21.90	22.16	21.47

Fulgent Genetics, Inc. Events

Time (UTC)	Country	Event
Friday, May 3, 2024
Time (UTC) 12:30	Country US	Event Q1 2024 Fulgent Genetics Inc Earnings Call Q1 2024 Fulgent Genetics Inc Earnings Call Forecast - Previous -
Time (UTC) 12:30	Country US	Event Q1 2024 Fulgent Genetics Inc Earnings Release Q1 2024 Fulgent Genetics Inc Earnings Release Forecast - Previous -
Thursday, May 16, 2024
Time (UTC) 16:00	Country US	Event Fulgent Genetics Inc Annual Shareholders Meeting Fulgent Genetics Inc Annual Shareholders Meeting Forecast - Previous -
Friday, May 17, 2024
Time (UTC) 16:00	Country US	Event Fulgent Genetics Inc Annual Shareholders Meeting Fulgent Genetics Inc Annual Shareholders Meeting Forecast - Previous -
Friday, August 2, 2024
Time (UTC) 12:30	Country US	Event Q2 2024 Fulgent Genetics Inc Earnings Release Q2 2024 Fulgent Genetics Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	618.968	992.584	421.712	32.528	21.351
Revenue	618.968	992.584	421.712	32.528	21.351
Cost of Revenue, Total	252.067	215.533	89.807	14.107	10.697
Gross Profit	366.901	777.051	331.905	18.421	10.654
Total Operating Expense	440.441	316.631	135.908	32.956	26.421
Selling/General/Admin. Expenses, Total	149.992	75.171	30.167	12.312	10.19
Research & Development	28.91	24.219	11.58	6.537	5.534
Operating Income	178.527	675.953	285.804	-0.428	-5.07
Interest Income (Expense), Net Non-Operating	5.498	1.347	1.526	0.837	0.434
Net Income Before Taxes	184.025	677.3	287.33	0.409	-4.636
Net Income After Taxes	141.923	502.505	214.798	0.366	-4.672
Net Income Before Extra. Items	143.403	507.364	214.31	-0.411	-5.607
Total Extraordinary Items					0
Net Income	143.403	507.364	214.31	-0.411	-5.607
Income Available to Common Excl. Extra. Items	143.403	507.364	214.31	-0.411	-5.607
Income Available to Common Incl. Extra. Items	143.403	507.364	214.31	-0.411	-5.607
Dilution Adjustment
Diluted Net Income	143.403	507.364	214.31	-0.411	-5.607
Diluted Weighted Average Shares	30.964	30.976	24.056	18.709	17.978
Diluted EPS Excluding Extraordinary Items	4.63128	16.3793	8.9088	-0.02197	-0.31188
Diluted Normalized EPS	4.70538	16.3793	9.0441	-0.02197	-0.31188
Equity In Affiliates	0	3.734	-0.488	-0.777	-0.935
Dividends per Share - Common Stock Primary Issue
Unusual Expense (Income)	2.975		4.354
Depreciation / Amortization	6.497	1.708
Minority Interest	1.48	1.125

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	67.853	66.168	67.704	105.655	125.341
Revenue	67.853	66.168	67.704	105.655	125.341
Cost of Revenue, Total	47.281	47.357	54.717	59.56	60.065
Gross Profit	20.572	18.811	12.987	46.095	65.276
Total Operating Expense	87.651	90.992	104.256	105.303	112.547
Selling/General/Admin. Expenses, Total	28.716	31.885	39.046	36.125	41.106
Research & Development	9.692	9.782	8.509	7.507	6.905
Operating Income	-19.798	-24.824	-36.552	0.352	12.794
Interest Income (Expense), Net Non-Operating	5.098	3.775	3.09	1.405	0.958
Net Income Before Taxes	-14.7	-21.049	-33.462	1.757	13.752
Net Income After Taxes	-11.59	-15.849	-24.076	1.343	11.099
Equity In Affiliates			0	0	0
Net Income Before Extra. Items	-11.229	-15.34	-23.832	1.719	11.537
Net Income	-11.229	-15.34	-23.832	1.719	11.537
Income Available to Common Excl. Extra. Items	-11.229	-15.34	-23.832	1.719	11.537
Income Available to Common Incl. Extra. Items	-11.229	-15.34	-23.832	1.719	11.537
Diluted Net Income	-11.229	-15.34	-23.832	1.719	11.537
Diluted Weighted Average Shares	29.813	29.536	29.62	30.867	31.189
Diluted EPS Excluding Extraordinary Items	-0.37665	-0.51937	-0.80459	0.05569	0.36991
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-0.37665	-0.51937	-0.80516	0.05829	0.44485
Minority Interest	0.361	0.509	0.244	0.376	0.438
Depreciation / Amortization	1.962	1.968	2.01	2.006	1.575
Unusual Expense (Income)	0		-0.026	0.105	2.896

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	627.873	611.96	523.616	37.079	39.543
Cash and Short Term Investments	526.235	450.499	299.367	28.269	31.034
Cash & Equivalents	79.506	164.894	87.426	11.965	6.736
Short Term Investments	446.729	285.605	211.941	16.304	24.298
Total Receivables, Net	90.544	145.011	204.076	7.245	7.489
Accounts Receivable - Trade, Net	52.749	139.149	185.236	6.705	5.948
Prepaid Expenses	6.814	4.244	3.682	1.288	0.706
Other Current Assets, Total	4.28	12.206	16.491	0.277	0.314
Total Assets	1386.05	1278.72	700.461	88.756	53.904
Property/Plant/Equipment, Total - Net	98.921	71.163	41.027	8.607	6.446
Property/Plant/Equipment, Total - Gross	142.202	90.793	51.947	16.597	12.332
Accumulated Depreciation, Total	-43.281	-19.63	-10.92	-7.99	-5.886
Long Term Investments	326.648	485.047	132.502	42.819	7.898
Other Long Term Assets, Total	38.941	23.739	3.316	0.251	0.017
Total Current Liabilities	88.107	105.31	130.115	3.723	2.738
Accounts Payable	23.093	20.494	26.488	1.581	1.313
Accrued Expenses	24.981	17.689	8.713	1.753	1.425
Notes Payable/Short Term Debt	20.638	21.284	15.019	0	0
Other Current Liabilities, Total	18.452	45.511	79.895	0.389
Total Liabilities	119.368	119.971	131.074	5.979	2.752
Total Long Term Debt	1.818	1.398	0	0	0
Deferred Income Tax	9.836	0.725	0.377
Other Liabilities, Total	16.417	5.407	0.582	2.256	0.014
Total Equity	1266.69	1158.75	569.387	82.777	51.152
Common Stock	0.003	0.003	0.003	0.002	0.002
Additional Paid-In Capital	486.585	501.908	418.065	146.058	114.203
Retained Earnings (Accumulated Deficit)	801	657.597	150.881	-63.429	-63.018
Other Equity, Total	-20.903	-0.759	0.438	0.146	-0.035
Total Liabilities & Shareholders’ Equity	1386.05	1278.72	700.461	88.756	53.904
Total Common Shares Outstanding	29.438	30.16	28.178	21.483	18.172
Preferred Stock - Non Redeemable, Net			0	0	0
Goodwill, Net	143.027	50.897
Intangibles, Net	150.643	35.914
Current Port. of LT Debt/Capital Leases	0.943	0.332
Capital Lease Obligations	1.818	1.398
Minority Interest	3.19	7.131

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	549.855	528.289	580.723	627.873	696.614
Cash and Short Term Investments	467.802	458.431	504.485	526.235	571.06
Cash & Equivalents	84.076	58.348	66.172	79.506	168.77
Short Term Investments	383.726	400.083	438.313	446.729	402.29
Total Receivables, Net	69.593	57.026	64.641	90.544	109.646
Accounts Receivable - Trade, Net	49.277	34.809	43.549	52.749	104.159
Prepaid Expenses	7.583	7.301	6.875	6.814	8.399
Other Current Assets, Total	4.877	5.531	4.722	4.28	7.509
Total Assets	1358.4	1354.58	1376.77	1386.05	1405.78
Property/Plant/Equipment, Total - Net	99.115	103.196	94.853	98.921	101.18
Property/Plant/Equipment, Total - Gross	146.223	152.862	140.992	142.202	137.146
Accumulated Depreciation, Total	-47.108	-49.666	-46.139	-43.281	-35.966
Long Term Investments	383.659	388.383	366.833	326.648	346.946
Other Long Term Assets, Total	39.436	46.266	42.539	38.941	52.876
Total Current Liabilities	61.421	64.819	81.939	88.107	102.522
Accounts Payable	15.772	20.607	22.08	23.093	14.481
Accrued Expenses	21.031	22.229	21.088	24.981	25.101
Notes Payable/Short Term Debt	2.89	4.56	20.607	20.638	20.48
Other Current Liabilities, Total	21.191	16.888	17.21	18.452	41.533
Total Liabilities	99.7	94.814	112.319	119.368	128.735
Total Long Term Debt	0.894	1.03	1.575	1.818	2.05
Deferred Income Tax	19.388	9.836	9.836	9.836	1.826
Other Liabilities, Total	14.861	15.566	14.498	16.417	17.987
Total Equity	1258.7	1259.76	1264.45	1266.69	1277.05
Preferred Stock - Non Redeemable, Net
Common Stock	0.003	0.003	0.003	0.003	0.003
Additional Paid-In Capital	514.262	506.075	495.981	486.585	477.814
Retained Earnings (Accumulated Deficit)	761.324	774.431	785.66	801	824.832
Other Equity, Total	-16.891	-20.746	-17.196	-20.903	-25.602
Total Liabilities & Shareholders’ Equity	1358.4	1354.58	1376.77	1386.05	1405.78
Total Common Shares Outstanding	30.035	29.917	29.692	29.438	29.681
Goodwill, Net	141.844	141.97	143.12	143.027	120.313
Intangibles, Net	144.489	146.473	148.699	150.643	87.853
Long Term Debt
Minority Interest	3.136	3.563	4.471	3.19	4.35
Current Port. of LT Debt/Capital Leases	0.537	0.535	0.954	0.943	0.927
Capital Lease Obligations	0.894	1.03	1.575	1.818	2.05

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	141.923	506.239	214.31	-0.411	-5.607
Cash From Operating Activities	253.52	538.577	140.628	5.517	-0.675
Cash From Operating Activities	32.662	11.004	2.962	2.107	2.163
Deferred Taxes	-8.28	-8.188	-1.775	-0.021	0.036
Non-Cash Items	85.21	32.198	16.582	4.757	3.977
Cash Taxes Paid	56.193	237.069	20.612	0.02	0.001
Changes in Working Capital	2.005	-2.676	-91.451	-0.915	-1.244
Cash From Investing Activities	-261.314	-546.548	-326.438	-29.046	0.95
Capital Expenditures	-18.775	-23.844	-35.13	-1.182	-2.322
Other Investing Cash Flow Items, Total	-242.539	-522.704	-291.308	-27.864	3.272
Cash From Financing Activities	-77.141	85.405	261.251	28.775	0.015
Financing Cash Flow Items	0	0.01			0
Total Cash Dividends Paid
Issuance (Retirement) of Stock, Net	-76.074	85.406	246.232	28.775	0.015
Net Change in Cash	-85.388	77.468	75.461	5.229	0.246
Foreign Exchange Effects	-0.453	0.034	0.02	-0.017	-0.044
Issuance (Retirement) of Debt, Net	-1.067	-0.011	15.019

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-15.849	141.923	165.999	164.656	153.557
Cash From Operating Activities	-7.907	253.52	220.313	199.537	188.411
Cash From Operating Activities	6.879	32.662	22.86	13.04	4.695
Deferred Taxes	-5.2	-8.28	-4.934	-7.639	-5.497
Non-Cash Items	11.056	85.21	57.419	39.227	20.84
Cash Taxes Paid	1.68	56.193	56.181	54.982	0.435
Changes in Working Capital	-4.793	2.005	-21.031	-9.747	14.816
Cash From Investing Activities	-4.354	-261.314	-168.715	-213.004	0.688
Capital Expenditures	-2.034	-18.775	-14.053	-8.618	-5.36
Other Investing Cash Flow Items, Total	-2.32	-242.539	-154.662	-204.386	6.048
Cash From Financing Activities	-1.101	-77.141	-47.548	-12.086	-0.934
Issuance (Retirement) of Stock, Net	-0.869	-76.074	-46.712	-11.488	-0.478
Issuance (Retirement) of Debt, Net	-0.232	-1.067	-0.836	-0.598	-0.456
Foreign Exchange Effects	0.028	-0.453	-0.174	-0.561	0.01
Net Change in Cash	-13.334	-85.388	3.876	-26.114	188.175
Financing Cash Flow Items		0	0	0

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Fulgent Genetics, Inc. Company profile

Fulgent Genetics (FLGT) is a global molecular diagnostic and genetic testing services provider.

Headquartered in Temple City, California, Fulgent Genetics was founded in 2011 as Fulgent Diagnostics. The company merges the fields of genetics, molecular biology and computer science to conduct diagnostic testing and genomic sequencing.It offers flexible testing options for physicians and patients.

Fulgent Genetics’ portfolio consists of more than 18,000 single genes for genetic testing, 800 rare disease tests, complete genome sequencing, complete genome Copy Number Variation (CNVs) analysis, mitochondrial sequencing and CLIA/CAP quality sequencing services.

The company has received accreditations from the Clinical Laboratory Improvement Amendments (CLIA), the College of American Pathologists (CAP), the California Clinical Laboratory, the Pennsylvania Clinical Laboratory, the Maryland Medical Laboratory, the New York State Clinical Laboratory and the Rhode Island Laboratory. Its strategic partnership with Helio Health aims to help the company commercialise tests for blood-based early cancer detection.

Fulgent Genetics Inc. stock began trading on the NASDAQ in 2016 under the ticker symbol FLGT.

You can track the FLGT share value and price history live at http://capital.com.

Industry:

Medical & Diagnostic Laboratories

4399 Santa Anita Ave
EL MONTE
CALIFORNIA 91731
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024